Farmas USA

Yo prefiero los lingotes. Mis gafas son TIF. Me da que con la línea de productos para el vulgo lo debe de estar petando.

yo los lingotazos....

AMRN

When it comes to the numbers, weekly prescriptions are indeed important for revenue and as a growth indicator, but the most important number in my mind when viewing the competitive landscape is the percentage of market share captured.

When the other drugs in the class are looked at week-to-week, we see that the two major competitors, Lovaza and Niaspan had a week-to-week drop of 6.29% and 5.2%, respectively, whereas Vascepa's week-to-week only showed a .3% drop. More importantly, Vascepa captured 2.64% of the total very high triglyceride market, which is its highest overall percentage to date

they show that even in a down week for script writing in the 'very high trig' market, Vascepa did not suffer the same kind of adverse drop because it gained scripts that previously had gone to either Lovaza or Niaspan. The market share of 2.64% reinforces the fact that Vascepa is slowly winning the market, and for investors this means that the company is proceeding with its goal to be the first-in-class choice therapy for very high triglycerides.

http://seekingalpha.com/article/1578932-amarin-how-to-actually-read-the-prescription-numbers?source=email_rt_article_title

Pues si es asi como dice, esto va viento en popa.

Que sigan bajando mientras nosotros nos mantenemos o incluso subimos :D

¿A la cabeza?

Si realmente las patentes de AMRN han conseguido el nivel de protección que el rechazo de la patente de EPA/DHA sugiere ... AMRN habria conseguido una EXCLUSIVIDAD 3 VECES SUPERIOR A LA DEL NCE

ONVO

http://seekingalpha.com/article/1579162-organovo-and-the-dream-of-printing-body-parts?source=email_rt_article_readmore

OREX

A lo mejor el ratil se deja llevar por la semana pasada y nos la sube un poquito más...

Resistencia en 7,73. Si no puede con ellos, a realizar Bºs